Caseware UK (AP4) 2023.0.135 2023.0.135 true72022-11-01truefalseResearch and experimental development on biotechnology7The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 04926092 2023-10-31 04926092 2022-11-01 2023-10-31 04926092 2021-11-01 2022-10-31 04926092 2022-10-31 04926092 c:Director1 2022-11-01 2023-10-31 04926092 d:CurrentFinancialInstruments 2023-10-31 04926092 d:CurrentFinancialInstruments 2022-10-31 04926092 d:CurrentFinancialInstruments d:WithinOneYear 2023-10-31 04926092 d:CurrentFinancialInstruments d:WithinOneYear 2022-10-31 04926092 d:ShareCapital 2023-10-31 04926092 d:ShareCapital 2022-10-31 04926092 d:SharePremium 2023-10-31 04926092 d:SharePremium 2022-10-31 04926092 d:RetainedEarningsAccumulatedLosses 2023-10-31 04926092 d:RetainedEarningsAccumulatedLosses 2022-10-31 04926092 c:FRS102 2022-11-01 2023-10-31 04926092 c:AuditExempt-NoAccountantsReport 2022-11-01 2023-10-31 04926092 c:FullAccounts 2022-11-01 2023-10-31 04926092 c:PrivateLimitedCompanyLtd 2022-11-01 2023-10-31 04926092 4 2022-11-01 2023-10-31 04926092 e:PoundSterling 2022-11-01 2023-10-31 iso4217:GBP xbrli:pure
Registered number: 04926092


OMNICYTE LIMITED








UNAUDITED

PAGES FOR FILING WITH REGISTRAR

FOR THE PERIOD ENDED 31 October 2023

 
OMNICYTE LIMITED
Registered number: 04926092

BALANCE SHEET
As at 31 October 2023

2023
2022
Note
£
£

  

Current assets
  

Debtors: amounts falling due within one year
 3 
102
102

Cash at bank and in hand
 4 
-
504

  
102
606

Creditors: amounts falling due within one year
 5 
(30,578)
(24,576)

Net current liabilities
  
 
 
(30,476)
 
 
(23,970)

Total assets less current liabilities
  
(30,476)
(23,970)

  

Net liabilities
  
(30,476)
(23,970)


Capital and reserves
  

Called up share capital 
  
106
106

Share premium account
  
199,996
199,996

Profit and loss account
  
(230,578)
(224,072)

  
(30,476)
(23,970)


Page 1

 
OMNICYTE LIMITED
Registered number: 04926092
    
BALANCE SHEET (CONTINUED)
As at 31 October 2023

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




................................................
Professor N Habib
Director

Date: 10 July 2024

The notes on pages 3 to 4 form part of these financial statements.

Page 2

 
OMNICYTE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
For the Year Ended 31 October 2023

1.Accounting policies

 
1.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
1.2

Exceptional items

Exceptional items are transactions that fall within the ordinary activities of the Company but are presented separately due to their size or incidence.

 
1.3

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
1.4

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
1.5

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
1.6

Financial instruments

The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.

The Company has elected to apply the recognition and measurement provisions of IFRS 9 Financial Instruments (as adopted by the UK Endorsement Board) with the disclosure requirements of Sections 11 and 12 and the other presentation requirements of FRS 102.


2.


Employees

The average monthly number of employees, including directors, during the year was 7 (2022 - 7).


3.


Debtors

2023
2022
£
£

Page 3

 
OMNICYTE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
For the Year Ended 31 October 2023

3.Debtors (continued)


Other debtors
102
102

102
102



4.


Cash and cash equivalents

2023
2022
£
£

Cash at bank and in hand
-
504

-
504



5.


Creditors: Amounts falling due within one year

2023
2022
£
£

Trade creditors
-
1,440

Amounts owed to group undertakings
2,000
2,000

Other creditors
27,138
19,696

Accruals and deferred income
1,440
1,440

30,578
24,576


 
Page 4